DoW Amyotrophic Lateral Sclerosis Research Program, Clinical Outcomes and Biomarkers Award

<p><strong>Summary: </strong>The fiscal year 2026 (FY26) Amyotrophic Lateral Sclerosis Research Program (ALSRP) Clinical Outcomes and Biomarkers Award (COBA) supports the development and/or validation of clinical outcomes and biomarkers to enrich clinical trials in amyotrophic lateral sclerosis (ALS). Projects can be relevant to a specific therapy, a class of therapeutics, or to a specific ALS subtype (such as a particular genetic mutation) and do not have to broadly apply to all patients.</p><p><br></p><p><strong>Distinctive Features: </strong>To meet the intent of the funding opportunity, applications may address <strong><em>clinical biomarkers and/or clinical outcomes</em></strong>. This may include the identification, development, and/or validation of promising biomarkers for ALS, which may include, but are not limited to susceptibility/risk, diagnostic, monitoring/disease progression, prognostic, predictive, response, or safety biomarkers. Clinical Outcomes projects may focus on the identification, development, and/or validation of clinician-, observer-, or patient-reported, and/or performance outcome measures for ALS. Projects may include the optimization of current outcome measures already in use.</p><p><br></p><p>Applications may utilize digital health measures, including wearable devices, smart-phone sensors, video or voice recordings, imaging studies, or other devices which record disease-relevant physiological data and/or outcomes.</p><p><br></p><p>Community Collaboration is an important element of the FY26 ALSRP COBA. Applicants will be expected to articulate how the proposed research question or study design was informed by the</p><p>ALS lived experience community.</p>